Braveheart Bio starts Phase 3 oHCM trial, reports Q2 2026 resultsSep 8Quarterly updateBraveheart Bio, Inc.
Braveheart Bio registers Phase 3 trial of BHB-1893 for obstructive HCMAug 10Trial updateBHB-1893Braveheart Bio, Inc.
Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893Jul 14FinancingBHB-1893Braveheart Bio, Inc.
Sign inSign in